Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Compared to the non-osteoporosis group, patients in the osteoporosis group were significantly older and had significantly lower levels of GNRI, BMI, lumbar spine T-score, total protein, albumin, uric acid, albumin-corrected calcium, serum phosphorus, and 25-hydroxyvitamin D (all p < 0.05).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A retrospective observational study was conducted, enrolling 324 postmenopausal female patients with T2DM who were hospitalized at our hospital from September 2021 to November 2024.

Source: Abstract.

Participants were divided into an osteoporosis group (T-score ≤ − 2.5, n = 141) and a non-osteoporosis group (T-score > − 2.5, n = 183) based on lumbar spine bone mineral density (BMD) measured by dual-energy X-ray absorptiometry.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

Association between the nutritional risk index and postmenopausal osteoporosis in patients with type 2 diabetes mellitus

Observational study · Frontiers in Nutrition · 2026

Original publication title

Association between the nutritional risk index and postmenopausal osteoporosis in patients with type 2 diabetes mellitus

Abuduwupuer Haibier; Hang Lin; Wei Liu; Wencui Li

Copyright © 2026 Haibier, Lin, Liu and Li.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In summary, among postmenopausal women with T2DM, a higher GNRI value is independently associated with a lower risk of osteoporosis. A lower GNRI level is significantly associated with an increased risk of osteoporosis and demonstrates moderate discriminatory ability for identifying this condition in the study population. These findings suggest that GNRI may serve as a simple and useful auxiliary indicator for assessing skeletal health risk in postmenopausal T2DM patients. For individuals with low GNRI values, enhanced nutritional evaluation and bone mineral density monitoring should be considered to facilitate early prevention and management of osteoporosis and related fractures.

Further prospective studies are warranted to validate the clinical utility of GNRI in this population.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To investigate the association between the Geriatric Nutritional Risk Index (GNRI) and the presence of postmenopausal osteoporosis (PMOP) in elderly female patients with type 2 diabetes mellitus (T2DM), and to evaluate the discriminatory ability of GNRI for PMOP in this population.

Source: Objective

Study methods

What methods does the paper describe?

2.1

Patient selection

This was a single-center, retrospective, observational study. Data were derived from postmenopausal female patients (aged ≥60 years) with T2DM who were hospitalized at our hospital between September 2021 and November 2024. Based on strict inclusion and exclusion criteria, a total of 324 patients were ultimately enrolled in the analysis. The study protocol was approved by the Institutional Review Board of The Sixth Affiliated Hospital of Xinjiang Medical University. As a retrospective analysis utilizing only anonymized existing clinical data without imposing additional risks, the ethics committee granted a waiver of individual informed consent.

2.2

Inclusion criteria

The inclusion criteria were as follows: (1) diagnosis of T2DM based on established criteria; (2) age ≥60 years; (3) postmenopausal status; and (4) availability of complete records for height and weight measurements, dual-energy X-ray absorptiometry (DXA) scans for BMD, and required blood biochemical and bone metabolism marker tests during the hospitalization.

2.3

Exclusion criteria

Patients were excluded if they met any of the following criteria: (1) comorbid conditions known to affect bone metabolism or nutritional status, such as malignancies or severe hepatic or renal insufficiency; (2) diagnosis of diabetes mellitus other than T2DM (e.g., type 1 diabetes); (3) presence of thyroid or parathyroid disorders; (4) long-term use of medications affecting bone metabolism (e.g., glucocorticoids); (5) severe psychological or cognitive impairment precluding adequate cooperation; or (6) incomplete clinical data.

2.4

Diagnostic criteria

2.4.1
Diagnostic criteria for osteoporosis

The diagnosis of OP was established according to the 2022 Chinese guidelines for the diagnosis and treatment of primary osteoporosis (10). In addition, we referred to the Chinese expert consensus on the management of fracture risk in patients with diabetes, which was jointly issued by the Chinese Society of Endocrinology and three other national societies (11). According to these guidelines, lumbar spine BMD was measured using dual-energy X-ray absorptiometry (DXA). A T-score ≥ − 1.0 was classified as normal bone mass, a T-score between −2.5 and −1.0 as osteopenia, and a T-score ≤ − 2.5 as osteoporosis.

While it is recognized that this T-score threshold may underestimate fracture risk in diabetic patients, it remains the current practical diagnostic criterion for initiating anti-osteoporosis therapy in clinical practice in China, as recommended by the consensus (11).

2.4.2
Diagnostic criteria for T2DM

The diagnosis of T2DM was based on the criteria outlined in the Chinese guidelines for the prevention and treatment of type 2 diabetes (2020 edition) (12). Furthermore, type 1 diabetes and other specific types of diabetes were rigorously excluded. Features leading to exclusion included: age of onset <30 years, presentation with classic symptoms of polydipsia, polyphagia, polyuria, and weight loss or with ketoacidosis at onset, non-obese body type, significantly reduced C-peptide levels, or the presence of insulin autoantibodies.

2.5

Clinical data collection

Clinical data were collected retrospectively through the hospital information system. Data included:

  • 1) Basic information: age.

  • 2) Anthropometric measurements: Height (cm) and weight (kg) were measured by nurses with patients in a fasting state, wearing light clothing and without shoes. BMI was calculated as weight (kg) divided by height squared (m2).

  • 3) Laboratory parameters: Fasting venous blood samples were collected after an 8-h fast for analysis. Measured parameters included serum albumin (Alb), creatinine (Scr), uric acid (UA), calcium (Ca), phosphorus (P), magnesium (Mg), triglycerides (TG), total cholesterol (TC), 25-hydroxyvitamin D [25(OH)D], glycated hemoglobin (HbA1c), eGFR, hemoglobin (Hb), prealbumin (PA), and the bone turnover markers β-C-terminal telopeptide of type I collagen (β-CTx) and procollagen type I N-terminal propeptide (PINP). To account for the influence of albumin levels on calcium measurements, the albumin-corrected calcium was calculated using the following standard formula: Corrected calcium (mmol/L) = total calcium (mmol/L) + 0.02 × [40: serum albumin (g/L)].

  • a) Bone Mineral Density Measurement: Lumbar spine (L1-L4) bone mineral density (g/cm2) and corresponding T-scores were measured by certified radiology technicians using a DXA scanner.

  • b) Calculation of GNRI:

GNRI was calculated using the following formula (13):

GNRI = 1.489 × serum albumin (g/L) + 41.7 × (current weight/ideal weight).

Ideal body weight for women was calculated as: Height (cm): 100: [(Height (cm): 150)/2.5].

If the patient’s current weight exceeded the calculated ideal weight, the ratio (current weight / ideal weight) was set to 1 for the calculation.

Based on the original study by Bouillanne et al. (13), a GNRI value ≤ 98 was defined as indicating nutritional risk, while a GNRI value > 98 was defined as no nutritional risk. This cutoff has been widely validated in elderly and chronically ill populations, including patients with type 2 diabetes (8, 13).

2.6

Statistical analysis

Statistical analyses were performed using SPSS software (version 26.0). Continuous data conforming to a normal distribution were presented as mean ± standard deviation (x-±s) and compared between groups using the independent samples t-test. Non-normally distributed continuous data were presented as median with interquartile range [M (P25, P75)] and compared using the Mann: Whitney U test. Categorical data were expressed as numbers with percentages [n (%)] and compared using the Chi-square test. The correlation between GNRI and various clinical parameters was examined using Pearson’s correlation analysis for normally distributed data and Spearman’s rank correlation analysis for non-normally distributed data.

Binary logistic regression analysis was employed to identify independent risk factors for postmenopausal osteoporosis (PMOP). The predictive performance of GNRI for PMOP was evaluated using Receiver Operating Characteristic (ROC) curve analysis, and the area under the curve (AUC) was calculated. A two-tailed p-value of less than 0.05 was considered statistically significant. Variables with a p-value < 0.05 in univariate analysis, along with GNRI, were entered into the multivariate model using a forward stepwise method; variables that did not differ significantly between groups in univariate analysis were not included to maintain model parsimony.

Source: Subjects and methods Source: Subjects and methods Source: Subjects and methods Source: Subjects and methods Source: Subjects and methods Source: Subjects and methods

Results: Participant flow analysis

A total of 324 postmenopausal female patients with T2DM who met the eligibility criteria were enrolled in this study. Based on the BMD T-scores determined by DXA, participants were categorized into two groups: the non-osteoporosis group (T-score > − 2.5; n = 183) and the osteoporosis group (T-score ≤ − 2.5; n = 141). Complete clinical data were available for all enrolled cases, and all were included in the final statistical analysis without any loss to follow-up or data exclusion.

Source: Participant flow analysis

Results: Grouping flowchart

The flowchart detailing the patient selection and group assignment process is presented in Figure 1.

Figure 1

Flow chart of patient assignment.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Grouping flowchart Source: Grouping flowchart

Comparison of clinical indicators between different nutritional risk groups

Results: Comparison of clinical indicators between different nutritional risk groups

In a secondary analysis, patients were stratified according to their GNRI values using a cutoff of 98 (10). Patients with nutritional risk (GNRI ≤ 98, n = 115) were significantly older, and had significantly lower BMI, lumbar spine BMD, T-score, 25(OH)D, total protein, uric acid, albumin-corrected calcium, phosphorus, magnesium, and triglycerides compared to those without nutritional risk (GNRI > 98, n = 209) (all p < 0.05, data not shown). These findings further support the association between GNRI and bone-related parameters.

Source: Comparison of clinical indicators between different nutritional risk groups

Binary logistic regression analysis of risk factors for postmenopausal osteoporosis

Results: Binary logistic regression analysis of risk factors for postmenopausal osteoporosis

Using the presence or absence of osteoporosis as the dependent variable, variables identified as significant in the univariate analysis along with GNRI were included in a multivariate binary logistic regression analysis (forward stepwise method). The results (Table 3) indicated that age (OR = 1.092, 95% CI: 1.038 to 1.149, p = 0.001) was an independent risk factor for PMOP in postmenopausal female patients with T2DM, while GNRI (OR = 0.812, 95% CI: 0.680 to 0.969, p = 0.021) was independently associated with a lower risk of PMOP.

Table 3

Multivariate binary logistic regression analysis of risk factors for postmenopausal osteoporosis.

Variableβ coefficientStandard errorWald χ2 p OR value95% CI
Age0.0880.02710.724 0.001 1.092 1.038 to 1.149
GNRI−0.2080.0905.321 0.021 0.812 0.680 to 0.969
Constant3.2451.5024.6690.03125.672Not reported

OR, odds ratio; CI, confidence interval; GNRI, Geriatric Nutritional Risk Index.Bold values represent statistically significant differences.

Source: Binary logistic regression analysis of risk factors for postmenopausal osteoporosis Source: Binary logistic regression analysis of risk factors for postmenopausal osteoporosis

Discriminatory ability of GNRI for postmenopausal osteoporosis

Results: Discriminatory ability of GNRI for postmenopausal osteoporosis

ROC curve analysis demonstrated (Figure 2) that the AUC for GNRI in discriminating PMOP in postmenopausal women with T2DM was 0.769 (95% CI: 0.718 to 0.820, p < 0.001), indicating moderate discriminatory ability. The optimal cut-off value was 101.2, as determined by maximizing the Youden index, yielding a sensitivity of 70.2% and a specificity of 73.8% (Youden index = 0.440).

Figure 2

ROC curve of GNRI for discriminating postmenopausal osteoporosis.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Discriminatory ability of GNRI for postmenopausal osteoporosis Source: Discriminatory ability of GNRI for postmenopausal osteoporosis

Discussion

Through a retrospective cohort analysis of 324 postmenopausal female patients with T2DM, this study systematically investigated the association between the GNRI and PMOP, as well as its discriminatory ability. The core findings reveal that GNRI values were significantly lower in the osteoporosis group compared to the non-osteoporosis group. Furthermore, multivariate analysis identified GNRI as independently associated with a lower risk of PMOP, demonstrating moderate discriminatory ability for PMOP with an AUC of 0.769. This finding holds significant importance within the context of the existing literature.

Previous research on diabetes and bone health has predominantly focused on the effects of hyperglycemia, insulin resistance, accumulation of advanced glycation end products (AGEs), or specific antidiabetic medications. Our study expands the perspective to the fundamental and modifiable dimension of systemic nutritional status (14, 15). These findings align with the original concept proposed by Bouillanne et al., who introduced GNRI to assess the link between nutritional risk and clinical outcomes in elderly patients, and further specify its application to the complex field of diabetic bone disease (13).

GNRI integrates measures of protein reserve (via serum albumin) and energy balance (via body weight status), which correspond to the two pillars of maintaining skeletal health: adequate protein supply is essential for sufficient bone matrix synthesis, while appropriate body weight provides the necessary mechanical load for bone mass preservation (16 to 18). The positive correlations observed in this study between GNRI and indicators such as lumbar spine BMD, serum calcium, and 25-hydroxyvitamin D suggest that nutritional risk may act as a critical link connecting diabetic metabolic dysregulation to increased bone fragility, potentially by disrupting the homeostasis of key substances involved in bone mineralization and affecting the skeletal structure itself.

This study found that GNRI values were significantly lower in patients in the osteoporosis group compared to the non-osteoporosis group, which is consistent with observations from multiple studies in elderly or chronically ill populations. As a composite index, GNRI encompasses both serum albumin (reflecting protein nutritional status) and body weight status (reflecting energy balance) (19). This study further revealed that GNRI showed strong positive correlations with skeletal indicators such as lumbar spine T-score (rs = 0.485, p < 0.001), and was also significantly correlated with levels of key nutrients involved in bone metabolism, including albumin-corrected calcium and 25(OH)D.

This suggests that the “nutritional risk” represented by GNRI is not a single deficiency, but rather a state of systemic malnutrition closely associated with bone health. It is noteworthy that, although T2DM patients are traditionally associated with obesity, the osteoporosis group in this study had a significantly lower BMI, and GNRI was positively correlated with BMI (20). This highlights the importance of emphasizing both “quality and weight management” in diabetes care: the need to control blood glucose while also preventing skeletal damage resulting from excessively low body weight and malnutrition (21, 22).

A study by Am et al. found that approximately half of the female OP patients had vitamin D levels below the normal range. Since 25(OH)D is the key hormone regulating intestinal calcium absorption, its deficiency directly impedes normal calcium uptake, leading to calcium imbalance in the body (23).

Multivariate logistic regression confirmed that GNRI remained independently associated with a lower risk of PMOP after adjusting for confounders such as age. The optimal cut-off value of 101.2, identified through ROC curve analysis, provides an objective and quantifiable threshold for identifying individuals at potential risk. With a sensitivity of approximately 70% and a specificity of around 74%, GNRI demonstrates potential utility as a low-cost, easily accessible indicator for risk stratification. However, these findings should be interpreted with caution given the cross-sectional design of the study, and the clinical utility of GNRI requires further validation in prospective cohorts.

Although it cannot replace DXA as the diagnostic gold standard, this index may assist in identifying postmenopausal T2DM patients with high nutritional risk who could be prioritized for further bone health evaluation. However, the clinical utility of GNRI for guiding interventions requires validation in prospective studies. This suggests a potential role for GNRI in integrating nutritional assessment into skeletal health risk stratification (8, 17).

The association between GNRI and PMOP may be mediated through multiple biological pathways (24). Firstly, hypoalbuminemia may directly impair bone matrix synthesis and affect the transport of vitamin D and its binding proteins, indirectly leading to disturbances in calcium and phosphorus metabolism and secondary hyperparathyroidism (6, 25). Secondly, low body weight and concomitant muscle loss reduce the mechanical load on bones, weakening the key mechanical stimuli necessary for maintaining bone mass (26, 27).

Additionally, malnutrition is often accompanied by a state of chronic low-grade inflammation, where elevated inflammatory cytokines (such as TNF-α and IL-6) can activate signaling pathways such as nuclear factor kappa B (NF-κB), promoting osteoclastogenesis and inhibiting osteogenesis (26, 28). Therefore, a decline in GNRI can be regarded as a comprehensive composite indicator, signaling that multiple adverse skeletal factors including protein-energy malnutrition, increased inflammatory burden, and diminished mechanical stimulation may be acting in concert to exacerbate skeletal fragility (29, 30).

Emerging evidence has highlighted the potential impact of glucose-lowering therapies on muscle mass, which may in turn influence bone health in patients with type 2 diabetes (31). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), while highly effective for glycemic control and weight reduction, have been associated with variable degrees of lean body mass loss, with some studies reporting that 40%: 60% of total weight loss may comprise lean mass (32). Although the clinical significance of this phenomenon remains debated, it is particularly relevant in older adults and those with pre-existing sarcopenia, who may be at greater risk of functional decline and fractures (33).

Importantly, sarcopenia and osteoporosis frequently co-exist as “osteosarcopenia,” a condition associated with higher fracture risk and worse clinical outcomes. In this context, nutritional status: as captured by GNRI: may serve as a critical link, because inadequate protein intake and energy deficiency not only contribute to bone loss but also exacerbate muscle wasting. Therefore, in patients receiving GLP-1 RAs or other weight-lowering therapies, regular assessment of nutritional risk using tools such as GNRI could help identify individuals who may benefit from targeted nutritional support and resistance exercise interventions to preserve both muscle and bone mass.

Further prospective studies are needed to explore whether nutritional optimization can mitigate therapy-induced lean mass loss and its skeletal consequences.

The conclusions of this study should be interpreted with consideration of the following limitations. First, as a single-center retrospective investigation, it is inherently susceptible to selection bias, and the design precludes the inference of a causal relationship between GNRI and PMOP; thus, the findings necessitate validation through prospective studies. Second, the cohort consisted solely of hospitalized patients, who likely present with greater disease severity and higher nutritional risk compared to the general community population. This may limit the generalizability of our results.

Third, despite adjusting for several known confounders, important variables potentially influencing bone metabolism such as precise postmenopausal duration, detailed dietary calcium intake, habitual physical activity levels, and the specific use of certain glucose-lowering medications were not fully accounted for, potentially leading to residual confounding. eGFR was collected and showed no significant difference between the two groups (p > 0.05); therefore, it was not entered into the multivariate logistic regression model. Nevertheless, given the well-established role of renal function in bone metabolism, we acknowledge that residual confounding related to renal function cannot be completely excluded, and future studies with larger sample sizes and more detailed renal function stratification are warranted.

Fourth, parathyroid hormone (PTH) levels were not measured in this study, as they were not part of the routine clinical protocol during the study period. Given the well-recognized role of secondary hyperparathyroidism in diabetic bone disease: particularly in the context of vitamin D deficiency and potential renal impairment: the absence of PTH data limits our ability to fully characterize the mechanisms underlying the observed associations. Fifth, acid: base balance parameters (e.g., serum bicarbonate) were not available in this study. Chronic metabolic acidosis, which may develop in T2DM patients with declining renal function or suboptimal glycemic control, is known to promote bone resorption through buffering mechanisms that mobilize calcium and phosphate from the bone matrix.

The absence of these data precludes assessment of this potential confounder and represents an additional limitation in interpreting the mechanistic pathways linking nutritional status to bone health. Sixth, the study did not incorporate a broader panel of bone turnover biomarkers or advanced imaging modalities to assess bone microstructure. Consequently, a deeper exploration of the underlying mechanisms from the perspectives of dynamic bone remodeling equilibrium and bone quality was not feasible.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion

Results

3.1

Participant flow analysis

A total of 324 postmenopausal female patients with T2DM who met the eligibility criteria were enrolled in this study. Based on the BMD T-scores determined by DXA, participants were categorized into two groups: the non-osteoporosis group (T-score > − 2.5; n = 183) and the osteoporosis group (T-score ≤ − 2.5; n = 141). Complete clinical data were available for all enrolled cases, and all were included in the final statistical analysis without any loss to follow-up or data exclusion.

3.2

Grouping flowchart

The flowchart detailing the patient selection and group assignment process is presented in Figure 1.

Figure 1

Flow chart of patient assignment.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.3

Comparison of clinical indicators between different bone density groups

As shown in Table 1, compared to the non-osteoporosis group, patients in the osteoporosis group were significantly older (Z = −5.236, p < 0.001). Meanwhile, their BMI (t = 2.854, p = 0.005), lumbar spine BMD (Z = −9.147, p < 0.001), serum total protein (t = 7.432, p < 0.001), albumin (t = 9.226, p < 0.001), uric acid (Z = −5.021, p < 0.001), serum calcium (Z = −4.388, p < 0.001), serum phosphorus (t = 3.031, p = 0.003), 25(OH)D (Z = −3.890, p < 0.001), and GNRI (Z = −8.530, p < 0.001) were all significantly lower, with the differences being statistically significant.

No statistically significant differences were observed between the two groups in serum creatinine, eGFR, magnesium, TG, or TC levels (p > 0.05).

Table 1

Comparison of baseline characteristics between different bone mineral density groups.

VariableNon-osteoporosis group (n = 183)Osteoporosis group (n = 141)Statistic P
Age (years)66.0 (63.0, 71.0)71.0 (67.0, 75.0)Z = −5.236<0.001
BMI (kg/m2)24.8 ± 3.423.5 ± 4.0t = 2.8540.005
Lumbar spine T-score−1.2 (−2.0, −0.2)−2.9 (−3.6, −2.6)Z = −9.512<0.001
Total protein (g/L)71.2 ± 6.265.8 ± 6.5t = 7.432<0.001
Albumin (g/L)42.1 ± 4.237.8 ± 3.9t = 9.226<0.001
Serum creatinine (μmol/L)59.0 (50.0, 69.0)58.0 (49.5, 68.0)Z = −0.6580.511
eGFR (mL/min/1.73m2)78.0 (68.0, 89.0)76.0 (66.0, 87.0)Z = −1.0230.306
Uric acid (μmol/L)330.0 (270.0, 388.0)268.0 (225.0, 340.0)Z = −5.021<0.001
Albumin-corrected calcium (mmol/L)2.31 (2.23, 2.39)2.24 (2.14, 2.32)Z = −4.412<0.001
Serum phosphorus (mmol/L)1.17 ± 0.181.11 ± 0.17t = 3.0310.003
Serum magnesium (mmol/L)0.88 (0.82, 0.94)0.86 (0.79, 0.92)Z = −1.7060.088
25(OH)D (ng/mL)16.8 (13.5, 20.1)14.9 (11.8, 18.0)Z = −3.890<0.001
TG (mmol/L)1.72 (1.25, 2.42)1.61 (1.10, 2.28)Z = −1.5950.111
TC (mmol/L)4.81 ± 1.024.75 ± 1.05t = 0.5240.601
GNRI103.8 (99.1, 108.5)96.5 (92.0, 101.1)Z = −8.530<0.001

Data are presented as mean ± standard deviation (x̅±s) for normally distributed variables, compared by independent samples t-test; or as median (interquartile range) [M (P25, P75)] for non-normally distributed variables, compared by Mann: Whitney U test. BMI, Body Mass Index; 25(OH)D, 25-hydroxyvitamin D; GNRI, Geriatric Nutritional Risk Index. Significant p values (<0.05) are highlighted in bold.

3.4

Comparison of clinical indicators between different nutritional risk groups

In a secondary analysis, patients were stratified according to their GNRI values using a cutoff of 98 (10). Patients with nutritional risk (GNRI ≤ 98, n = 115) were significantly older, and had significantly lower BMI, lumbar spine BMD, T-score, 25(OH)D, total protein, uric acid, albumin-corrected calcium, phosphorus, magnesium, and triglycerides compared to those without nutritional risk (GNRI > 98, n = 209) (all p < 0.05, data not shown). These findings further support the association between GNRI and bone-related parameters.

3.5

Correlation analysis between GNRI and clinical indicators

As shown in Table 2, Pearson/Spearman correlation analysis revealed that the GNRI was negatively correlated with age (rs = −0.203, p < 0.001). In contrast, GNRI showed positive correlations with BMI (r = 0.172, p = 0.002), lumbar spine T-score (rs = 0.485, p < 0.001), 25(OH)D (rs = 0.218, p < 0.001), serum total protein (r = 0.728, p < 0.001), uric acid (rs = 0.225, p < 0.001), serum calcium (rs = 0.532, p < 0.001), serum phosphorus (r = 0.165, p = 0.003), serum magnesium (rs = 0.168, p = 0.002), TG (rs = 0.161, p = 0.004), and TC (r = 0.148, p = 0.008).

No significant correlation was found between GNRI and serum creatinine (p > 0.05).

Table 2

Correlation analysis between GNRI and clinical indicators.

IndicatorCorrelation coefficient (r/rs) p
Age−0.203<0.001
BMI0.1720.002
T-score0.485<0.001
25(OH)D0.218<0.001
Total protein0.728<0.001
Serum creatinine−0.0100.854
Uric acid0.225<0.001
Albumin-corrected calcium0.528<0.001
Serum phosphorus0.1650.003
Serum magnesium0.1680.002
TG0.1610.004
TC0.1480.008

GNRI, Geriatric Nutritional Risk Index; BMI, Body Mass Index; BMD, Bone Mineral Density; 25(OH)D, 25-hydroxyvitamin D; TG, Triglycerides; TC, Total Cholesterol. “r” denotes Pearson’s correlation coefficient; “rs” denotes Spearman’s rank correlation coefficient.

3.6

Binary logistic regression analysis of risk factors for postmenopausal osteoporosis

Using the presence or absence of osteoporosis as the dependent variable, variables identified as significant in the univariate analysis along with GNRI were included in a multivariate binary logistic regression analysis (forward stepwise method). The results (Table 3) indicated that age (OR = 1.092, 95% CI: 1.038 to 1.149, p = 0.001) was an independent risk factor for PMOP in postmenopausal female patients with T2DM, while GNRI (OR = 0.812, 95% CI: 0.680 to 0.969, p = 0.021) was independently associated with a lower risk of PMOP.

Table 3

Multivariate binary logistic regression analysis of risk factors for postmenopausal osteoporosis.

Variableβ coefficientStandard errorWald χ2 p OR value95% CI
Age0.0880.02710.724 0.001 1.092 1.038 to 1.149
GNRI−0.2080.0905.321 0.021 0.812 0.680 to 0.969
Constant3.2451.5024.6690.03125.672Not reported

OR, odds ratio; CI, confidence interval; GNRI, Geriatric Nutritional Risk Index.Bold values represent statistically significant differences.

3.7

Discriminatory ability of GNRI for postmenopausal osteoporosis

ROC curve analysis demonstrated (Figure 2) that the AUC for GNRI in discriminating PMOP in postmenopausal women with T2DM was 0.769 (95% CI: 0.718 to 0.820, p < 0.001), indicating moderate discriminatory ability. The optimal cut-off value was 101.2, as determined by maximizing the Youden index, yielding a sensitivity of 70.2% and a specificity of 73.8% (Youden index = 0.440).

Figure 2

ROC curve of GNRI for discriminating postmenopausal osteoporosis.

Figure image at the original source: open the original paper. This file is not included in this text import.
Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results

Conclusion

In summary, among postmenopausal women with T2DM, a higher GNRI value is independently associated with a lower risk of osteoporosis. A lower GNRI level is significantly associated with an increased risk of osteoporosis and demonstrates moderate discriminatory ability for identifying this condition in the study population. These findings suggest that GNRI may serve as a simple and useful auxiliary indicator for assessing skeletal health risk in postmenopausal T2DM patients. For individuals with low GNRI values, enhanced nutritional evaluation and bone mineral density monitoring should be considered to facilitate early prevention and management of osteoporosis and related fractures.

Further prospective studies are warranted to validate the clinical utility of GNRI in this population.

Source: Conclusion
Authors’ abstract

Objective

To investigate the association between the Geriatric Nutritional Risk Index (GNRI) and the presence of postmenopausal osteoporosis (PMOP) in elderly female patients with type 2 diabetes mellitus (T2DM), and to evaluate the discriminatory ability of GNRI for PMOP in this population.

Methods

A retrospective observational study was conducted, enrolling 324 postmenopausal female patients with T2DM who were hospitalized at our hospital from September 2021 to November 2024. Participants were divided into an osteoporosis group (T-score ≤ − 2.5, n = 141) and a non-osteoporosis group (T-score > − 2.5, n = 183) based on lumbar spine bone mineral density (BMD) measured by dual-energy X-ray absorptiometry. Data on age, body mass index (BMI), BMD, serological indicators, and GNRI were collected and compared between the two groups.

Correlation analysis was performed to examine the relationship between GNRI and various parameters. Binary logistic regression was used to identify independent factors influencing PMOP. The predictive efficacy of GNRI was assessed using the receiver operating characteristic (ROC) curve.

Results

Compared to the non-osteoporosis group, patients in the osteoporosis group were significantly older and had significantly lower levels of GNRI, BMI, lumbar spine T-score, total protein, albumin, uric acid, albumin-corrected calcium, serum phosphorus, and 25-hydroxyvitamin D (all p < 0.05). Correlation analysis revealed that GNRI was negatively correlated with age (rs = −0.203, p < 0.001) and positively correlated with lumbar spine T-score (rs = 0.485, p < 0.001), albumin-corrected calcium (rs = 0.532, p < 0.001), and 25-hydroxyvitamin D (rs = 0.528, p < 0.001).

Multivariate logistic regression analysis identified age as an independent risk factor for PMOP (OR = 1.092, 95% CI: 1.038 to 1.149, p = 0.001), while GNRI was independently associated with a lower risk of PMOP (OR = 0.812, 95% CI: 0.680 to 0.969, p = 0.021). ROC curve analysis demonstrated that the area under the curve (AUC) for GNRI in discriminating PMOP was 0.769 (95% CI: 0.718 to 0.820, p < 0.001). The optimal cut-off value was 101.2, with a sensitivity of 70.2% and a specificity of 73.8%.

Conclusion

In postmenopausal female patients with T2DM, a higher GNRI value is independently associated with a lower risk of PMOP. GNRI demonstrates moderate discriminatory ability for identifying PMOP in this population and may serve as a simple and useful auxiliary indicator for assessing skeletal health risk in clinical practice, pending further prospective validation.

Read the full paper
1

Introduction

Type 2 diabetes mellitus (T2DM) and osteoporosis (OP) are two common chronic diseases that pose significant threats to the health of postmenopausal women. However, the relationship between them is complex. Contrary to the traditional view that patients with T2DM have higher bone mineral density (BMD), a growing body of evidence indicates that their fracture risk is paradoxically increased (1 to 3). This “diabetic bone paradox” suggests that T2DM affects bone quality through mechanisms beyond BMD, including impaired microarchitecture and abnormal bone turnover, making it a distinct condition termed “diabetes osteoporosis” by some investigators (4).

Consequently, identifying modifiable risk factors for osteoporosis in this specific population is of paramount clinical importance.

In patients with T2DM, declining renal function represents a critical link between metabolic dysregulation and bone fragility. As estimated glomerular filtration rate (eGFR) decreases, the 1α-hydroxylation of 25-hydroxyvitamin D in the kidney is progressively impaired, leading to reduced circulating levels of active 1,25-dihydroxyvitamin D (5). This, in turn, diminishes intestinal calcium absorption and contributes to secondary hyperparathyroidism, a state characterized by increased osteoclastic bone resorption and accelerated bone loss (6). Moreover, chronic kidney disease: commonly encountered in long-standing T2DM: is frequently accompanied by metabolic acidosis, even in its mild, subclinical form.

Under such conditions, the body mobilizes alkaline salts from bone to buffer excess hydrogen ions, resulting in the release of calcium and phosphate from the mineralized matrix and promoting osteoclast activity (7). Over time, this acid-induced bone resorption can further compromise bone mineral density and skeletal microarchitecture. Collectively, these interconnected pathways underscore the importance of considering both renal function and acid: base status in evaluating skeletal health in patients with T2DM.

Among the myriad factors affecting bone health in T2DM, nutritional status has emerged as a fundamental and particularly critical modifiable dimension (4). Patients with diabetes often face heightened nutritional risks due to strict dietary management, diabetes-related complications (e.g., gastroparesis, nephropathy), and the catabolic effects of chronic hyperglycemia. This nutritional vulnerability is not limited to protein-energy malnutrition but also includes deficiencies in micronutrients essential for bone metabolism, such as calcium and vitamin D (5). Importantly, the pathophysiology of diabetic osteoporosis is now understood to involve not just hyperglycemia, but also sarcopenia, chronic low-grade inflammation, and gut microbiota dysbiosis: all of which are closely intertwined with nutritional status (4).

Therefore, a comprehensive assessment of nutritional risk may offer a crucial window into understanding and managing skeletal fragility in this population.

Despite this recognized importance, current research largely focuses on the associations of single nutrients or isolated biomarkers with BMD in diabetic patients. There is a notable gap in studies utilizing a comprehensive, systematic nutritional risk assessment to evaluate its relationship with osteoporosis, particularly in the high-risk subgroup of postmenopausal women with T2DM (8). This population faces a convergence of risk factors: aging, estrogen deficiency, and the metabolic challenges of diabetes: making the integrated assessment of nutritional status a potentially powerful tool for risk stratification.

Given this gap, a retrospective study design offers an efficient approach to explore these associations using existing clinical data (9).

This study, designed as a retrospective observational analysis, aims to quantitatively evaluate the association between comprehensive nutritional risk status and the risk of osteoporosis in postmenopausal T2DM patients through systematic analysis of historical clinical data. The study seeks to delineate the distribution profile of the Geriatric Nutritional Risk Index (GNRI) within this specific population and, employing multivariate logistic regression models while controlling for known confounders, to test whether GNRI serves as an independent predictor of osteoporosis. Its core objective is to move beyond single nutritional indicators, providing new epidemiological evidence from the perspective of overall nutritional status to understand the pathophysiological mechanisms of diabetic bone disease.

2

Subjects and methods

2.1

Patient selection

This was a single-center, retrospective, observational study. Data were derived from postmenopausal female patients (aged ≥60 years) with T2DM who were hospitalized at our hospital between September 2021 and November 2024. Based on strict inclusion and exclusion criteria, a total of 324 patients were ultimately enrolled in the analysis. The study protocol was approved by the Institutional Review Board of The Sixth Affiliated Hospital of Xinjiang Medical University. As a retrospective analysis utilizing only anonymized existing clinical data without imposing additional risks, the ethics committee granted a waiver of individual informed consent.

2.2

Inclusion criteria

The inclusion criteria were as follows: (1) diagnosis of T2DM based on established criteria; (2) age ≥60 years; (3) postmenopausal status; and (4) availability of complete records for height and weight measurements, dual-energy X-ray absorptiometry (DXA) scans for BMD, and required blood biochemical and bone metabolism marker tests during the hospitalization.

2.3

Exclusion criteria

Patients were excluded if they met any of the following criteria: (1) comorbid conditions known to affect bone metabolism or nutritional status, such as malignancies or severe hepatic or renal insufficiency; (2) diagnosis of diabetes mellitus other than T2DM (e.g., type 1 diabetes); (3) presence of thyroid or parathyroid disorders; (4) long-term use of medications affecting bone metabolism (e.g., glucocorticoids); (5) severe psychological or cognitive impairment precluding adequate cooperation; or (6) incomplete clinical data.

2.4

Diagnostic criteria

2.4.1
Diagnostic criteria for osteoporosis

The diagnosis of OP was established according to the 2022 Chinese guidelines for the diagnosis and treatment of primary osteoporosis (10). In addition, we referred to the Chinese expert consensus on the management of fracture risk in patients with diabetes, which was jointly issued by the Chinese Society of Endocrinology and three other national societies (11). According to these guidelines, lumbar spine BMD was measured using dual-energy X-ray absorptiometry (DXA). A T-score ≥ − 1.0 was classified as normal bone mass, a T-score between −2.5 and −1.0 as osteopenia, and a T-score ≤ − 2.5 as osteoporosis.

While it is recognized that this T-score threshold may underestimate fracture risk in diabetic patients, it remains the current practical diagnostic criterion for initiating anti-osteoporosis therapy in clinical practice in China, as recommended by the consensus (11).

2.4.2
Diagnostic criteria for T2DM

The diagnosis of T2DM was based on the criteria outlined in the Chinese guidelines for the prevention and treatment of type 2 diabetes (2020 edition) (12). Furthermore, type 1 diabetes and other specific types of diabetes were rigorously excluded. Features leading to exclusion included: age of onset <30 years, presentation with classic symptoms of polydipsia, polyphagia, polyuria, and weight loss or with ketoacidosis at onset, non-obese body type, significantly reduced C-peptide levels, or the presence of insulin autoantibodies.

2.5

Clinical data collection

Clinical data were collected retrospectively through the hospital information system. Data included:

  • 1) Basic information: age.

  • 2) Anthropometric measurements: Height (cm) and weight (kg) were measured by nurses with patients in a fasting state, wearing light clothing and without shoes. BMI was calculated as weight (kg) divided by height squared (m2).

  • 3) Laboratory parameters: Fasting venous blood samples were collected after an 8-h fast for analysis. Measured parameters included serum albumin (Alb), creatinine (Scr), uric acid (UA), calcium (Ca), phosphorus (P), magnesium (Mg), triglycerides (TG), total cholesterol (TC), 25-hydroxyvitamin D [25(OH)D], glycated hemoglobin (HbA1c), eGFR, hemoglobin (Hb), prealbumin (PA), and the bone turnover markers β-C-terminal telopeptide of type I collagen (β-CTx) and procollagen type I N-terminal propeptide (PINP). To account for the influence of albumin levels on calcium measurements, the albumin-corrected calcium was calculated using the following standard formula: Corrected calcium (mmol/L) = total calcium (mmol/L) + 0.02 × [40: serum albumin (g/L)].

  • a) Bone Mineral Density Measurement: Lumbar spine (L1-L4) bone mineral density (g/cm2) and corresponding T-scores were measured by certified radiology technicians using a DXA scanner.

  • b) Calculation of GNRI:

GNRI was calculated using the following formula (13):

GNRI = 1.489 × serum albumin (g/L) + 41.7 × (current weight/ideal weight).

Ideal body weight for women was calculated as: Height (cm): 100: [(Height (cm): 150)/2.5].

If the patient’s current weight exceeded the calculated ideal weight, the ratio (current weight / ideal weight) was set to 1 for the calculation.

Based on the original study by Bouillanne et al. (13), a GNRI value ≤ 98 was defined as indicating nutritional risk, while a GNRI value > 98 was defined as no nutritional risk. This cutoff has been widely validated in elderly and chronically ill populations, including patients with type 2 diabetes (8, 13).

2.6

Statistical analysis

Statistical analyses were performed using SPSS software (version 26.0). Continuous data conforming to a normal distribution were presented as mean ± standard deviation (x-±s) and compared between groups using the independent samples t-test. Non-normally distributed continuous data were presented as median with interquartile range [M (P25, P75)] and compared using the Mann: Whitney U test. Categorical data were expressed as numbers with percentages [n (%)] and compared using the Chi-square test. The correlation between GNRI and various clinical parameters was examined using Pearson’s correlation analysis for normally distributed data and Spearman’s rank correlation analysis for non-normally distributed data.

Binary logistic regression analysis was employed to identify independent risk factors for postmenopausal osteoporosis (PMOP). The predictive performance of GNRI for PMOP was evaluated using Receiver Operating Characteristic (ROC) curve analysis, and the area under the curve (AUC) was calculated. A two-tailed p-value of less than 0.05 was considered statistically significant. Variables with a p-value < 0.05 in univariate analysis, along with GNRI, were entered into the multivariate model using a forward stepwise method; variables that did not differ significantly between groups in univariate analysis were not included to maintain model parsimony.

3

Results

3.1

Participant flow analysis

A total of 324 postmenopausal female patients with T2DM who met the eligibility criteria were enrolled in this study. Based on the BMD T-scores determined by DXA, participants were categorized into two groups: the non-osteoporosis group (T-score > − 2.5; n = 183) and the osteoporosis group (T-score ≤ − 2.5; n = 141). Complete clinical data were available for all enrolled cases, and all were included in the final statistical analysis without any loss to follow-up or data exclusion.

3.2

Grouping flowchart

The flowchart detailing the patient selection and group assignment process is presented in Figure 1.

Figure 1

Flow chart of patient assignment.

Figure image at the original source: open the original paper. This file is not included in this text import.
3.3

Comparison of clinical indicators between different bone density groups

As shown in Table 1, compared to the non-osteoporosis group, patients in the osteoporosis group were significantly older (Z = −5.236, p < 0.001). Meanwhile, their BMI (t = 2.854, p = 0.005), lumbar spine BMD (Z = −9.147, p < 0.001), serum total protein (t = 7.432, p < 0.001), albumin (t = 9.226, p < 0.001), uric acid (Z = −5.021, p < 0.001), serum calcium (Z = −4.388, p < 0.001), serum phosphorus (t = 3.031, p = 0.003), 25(OH)D (Z = −3.890, p < 0.001), and GNRI (Z = −8.530, p < 0.001) were all significantly lower, with the differences being statistically significant.

No statistically significant differences were observed between the two groups in serum creatinine, eGFR, magnesium, TG, or TC levels (p > 0.05).

Table 1

Comparison of baseline characteristics between different bone mineral density groups.

VariableNon-osteoporosis group (n = 183)Osteoporosis group (n = 141)Statistic P
Age (years)66.0 (63.0, 71.0)71.0 (67.0, 75.0)Z = −5.236<0.001
BMI (kg/m2)24.8 ± 3.423.5 ± 4.0t = 2.8540.005
Lumbar spine T-score−1.2 (−2.0, −0.2)−2.9 (−3.6, −2.6)Z = −9.512<0.001
Total protein (g/L)71.2 ± 6.265.8 ± 6.5t = 7.432<0.001
Albumin (g/L)42.1 ± 4.237.8 ± 3.9t = 9.226<0.001
Serum creatinine (μmol/L)59.0 (50.0, 69.0)58.0 (49.5, 68.0)Z = −0.6580.511
eGFR (mL/min/1.73m2)78.0 (68.0, 89.0)76.0 (66.0, 87.0)Z = −1.0230.306
Uric acid (μmol/L)330.0 (270.0, 388.0)268.0 (225.0, 340.0)Z = −5.021<0.001
Albumin-corrected calcium (mmol/L)2.31 (2.23, 2.39)2.24 (2.14, 2.32)Z = −4.412<0.001
Serum phosphorus (mmol/L)1.17 ± 0.181.11 ± 0.17t = 3.0310.003
Serum magnesium (mmol/L)0.88 (0.82, 0.94)0.86 (0.79, 0.92)Z = −1.7060.088
25(OH)D (ng/mL)16.8 (13.5, 20.1)14.9 (11.8, 18.0)Z = −3.890<0.001
TG (mmol/L)1.72 (1.25, 2.42)1.61 (1.10, 2.28)Z = −1.5950.111
TC (mmol/L)4.81 ± 1.024.75 ± 1.05t = 0.5240.601
GNRI103.8 (99.1, 108.5)96.5 (92.0, 101.1)Z = −8.530<0.001

Data are presented as mean ± standard deviation (x̅±s) for normally distributed variables, compared by independent samples t-test; or as median (interquartile range) [M (P25, P75)] for non-normally distributed variables, compared by Mann: Whitney U test. BMI, Body Mass Index; 25(OH)D, 25-hydroxyvitamin D; GNRI, Geriatric Nutritional Risk Index. Significant p values (<0.05) are highlighted in bold.

3.4

Comparison of clinical indicators between different nutritional risk groups

In a secondary analysis, patients were stratified according to their GNRI values using a cutoff of 98 (10). Patients with nutritional risk (GNRI ≤ 98, n = 115) were significantly older, and had significantly lower BMI, lumbar spine BMD, T-score, 25(OH)D, total protein, uric acid, albumin-corrected calcium, phosphorus, magnesium, and triglycerides compared to those without nutritional risk (GNRI > 98, n = 209) (all p < 0.05, data not shown). These findings further support the association between GNRI and bone-related parameters.

3.5

Correlation analysis between GNRI and clinical indicators

As shown in Table 2, Pearson/Spearman correlation analysis revealed that the GNRI was negatively correlated with age (rs = −0.203, p < 0.001). In contrast, GNRI showed positive correlations with BMI (r = 0.172, p = 0.002), lumbar spine T-score (rs = 0.485, p < 0.001), 25(OH)D (rs = 0.218, p < 0.001), serum total protein (r = 0.728, p < 0.001), uric acid (rs = 0.225, p < 0.001), serum calcium (rs = 0.532, p < 0.001), serum phosphorus (r = 0.165, p = 0.003), serum magnesium (rs = 0.168, p = 0.002), TG (rs = 0.161, p = 0.004), and TC (r = 0.148, p = 0.008).

No significant correlation was found between GNRI and serum creatinine (p > 0.05).

Table 2

Correlation analysis between GNRI and clinical indicators.

IndicatorCorrelation coefficient (r/rs) p
Age−0.203<0.001
BMI0.1720.002
T-score0.485<0.001
25(OH)D0.218<0.001
Total protein0.728<0.001
Serum creatinine−0.0100.854
Uric acid0.225<0.001
Albumin-corrected calcium0.528<0.001
Serum phosphorus0.1650.003
Serum magnesium0.1680.002
TG0.1610.004
TC0.1480.008

GNRI, Geriatric Nutritional Risk Index; BMI, Body Mass Index; BMD, Bone Mineral Density; 25(OH)D, 25-hydroxyvitamin D; TG, Triglycerides; TC, Total Cholesterol. “r” denotes Pearson’s correlation coefficient; “rs” denotes Spearman’s rank correlation coefficient.

3.6

Binary logistic regression analysis of risk factors for postmenopausal osteoporosis

Using the presence or absence of osteoporosis as the dependent variable, variables identified as significant in the univariate analysis along with GNRI were included in a multivariate binary logistic regression analysis (forward stepwise method). The results (Table 3) indicated that age (OR = 1.092, 95% CI: 1.038 to 1.149, p = 0.001) was an independent risk factor for PMOP in postmenopausal female patients with T2DM, while GNRI (OR = 0.812, 95% CI: 0.680 to 0.969, p = 0.021) was independently associated with a lower risk of PMOP.

Table 3

Multivariate binary logistic regression analysis of risk factors for postmenopausal osteoporosis.

Variableβ coefficientStandard errorWald χ2 p OR value95% CI
Age0.0880.02710.724 0.001 1.092 1.038 to 1.149
GNRI−0.2080.0905.321 0.021 0.812 0.680 to 0.969
Constant3.2451.5024.6690.03125.672Not reported

OR, odds ratio; CI, confidence interval; GNRI, Geriatric Nutritional Risk Index.Bold values represent statistically significant differences.

3.7

Discriminatory ability of GNRI for postmenopausal osteoporosis

ROC curve analysis demonstrated (Figure 2) that the AUC for GNRI in discriminating PMOP in postmenopausal women with T2DM was 0.769 (95% CI: 0.718 to 0.820, p < 0.001), indicating moderate discriminatory ability. The optimal cut-off value was 101.2, as determined by maximizing the Youden index, yielding a sensitivity of 70.2% and a specificity of 73.8% (Youden index = 0.440).

Figure 2

ROC curve of GNRI for discriminating postmenopausal osteoporosis.

Figure image at the original source: open the original paper. This file is not included in this text import.
4

Discussion

Through a retrospective cohort analysis of 324 postmenopausal female patients with T2DM, this study systematically investigated the association between the GNRI and PMOP, as well as its discriminatory ability. The core findings reveal that GNRI values were significantly lower in the osteoporosis group compared to the non-osteoporosis group. Furthermore, multivariate analysis identified GNRI as independently associated with a lower risk of PMOP, demonstrating moderate discriminatory ability for PMOP with an AUC of 0.769. This finding holds significant importance within the context of the existing literature.

Previous research on diabetes and bone health has predominantly focused on the effects of hyperglycemia, insulin resistance, accumulation of advanced glycation end products (AGEs), or specific antidiabetic medications. Our study expands the perspective to the fundamental and modifiable dimension of systemic nutritional status (14, 15). These findings align with the original concept proposed by Bouillanne et al., who introduced GNRI to assess the link between nutritional risk and clinical outcomes in elderly patients, and further specify its application to the complex field of diabetic bone disease (13).

GNRI integrates measures of protein reserve (via serum albumin) and energy balance (via body weight status), which correspond to the two pillars of maintaining skeletal health: adequate protein supply is essential for sufficient bone matrix synthesis, while appropriate body weight provides the necessary mechanical load for bone mass preservation (16 to 18). The positive correlations observed in this study between GNRI and indicators such as lumbar spine BMD, serum calcium, and 25-hydroxyvitamin D suggest that nutritional risk may act as a critical link connecting diabetic metabolic dysregulation to increased bone fragility, potentially by disrupting the homeostasis of key substances involved in bone mineralization and affecting the skeletal structure itself.

This study found that GNRI values were significantly lower in patients in the osteoporosis group compared to the non-osteoporosis group, which is consistent with observations from multiple studies in elderly or chronically ill populations. As a composite index, GNRI encompasses both serum albumin (reflecting protein nutritional status) and body weight status (reflecting energy balance) (19). This study further revealed that GNRI showed strong positive correlations with skeletal indicators such as lumbar spine T-score (rs = 0.485, p < 0.001), and was also significantly correlated with levels of key nutrients involved in bone metabolism, including albumin-corrected calcium and 25(OH)D.

This suggests that the “nutritional risk” represented by GNRI is not a single deficiency, but rather a state of systemic malnutrition closely associated with bone health. It is noteworthy that, although T2DM patients are traditionally associated with obesity, the osteoporosis group in this study had a significantly lower BMI, and GNRI was positively correlated with BMI (20). This highlights the importance of emphasizing both “quality and weight management” in diabetes care: the need to control blood glucose while also preventing skeletal damage resulting from excessively low body weight and malnutrition (21, 22).

A study by Am et al. found that approximately half of the female OP patients had vitamin D levels below the normal range. Since 25(OH)D is the key hormone regulating intestinal calcium absorption, its deficiency directly impedes normal calcium uptake, leading to calcium imbalance in the body (23).

Multivariate logistic regression confirmed that GNRI remained independently associated with a lower risk of PMOP after adjusting for confounders such as age. The optimal cut-off value of 101.2, identified through ROC curve analysis, provides an objective and quantifiable threshold for identifying individuals at potential risk. With a sensitivity of approximately 70% and a specificity of around 74%, GNRI demonstrates potential utility as a low-cost, easily accessible indicator for risk stratification. However, these findings should be interpreted with caution given the cross-sectional design of the study, and the clinical utility of GNRI requires further validation in prospective cohorts.

Although it cannot replace DXA as the diagnostic gold standard, this index may assist in identifying postmenopausal T2DM patients with high nutritional risk who could be prioritized for further bone health evaluation. However, the clinical utility of GNRI for guiding interventions requires validation in prospective studies. This suggests a potential role for GNRI in integrating nutritional assessment into skeletal health risk stratification (8, 17).

The association between GNRI and PMOP may be mediated through multiple biological pathways (24). Firstly, hypoalbuminemia may directly impair bone matrix synthesis and affect the transport of vitamin D and its binding proteins, indirectly leading to disturbances in calcium and phosphorus metabolism and secondary hyperparathyroidism (6, 25). Secondly, low body weight and concomitant muscle loss reduce the mechanical load on bones, weakening the key mechanical stimuli necessary for maintaining bone mass (26, 27).

Additionally, malnutrition is often accompanied by a state of chronic low-grade inflammation, where elevated inflammatory cytokines (such as TNF-α and IL-6) can activate signaling pathways such as nuclear factor kappa B (NF-κB), promoting osteoclastogenesis and inhibiting osteogenesis (26, 28). Therefore, a decline in GNRI can be regarded as a comprehensive composite indicator, signaling that multiple adverse skeletal factors including protein-energy malnutrition, increased inflammatory burden, and diminished mechanical stimulation may be acting in concert to exacerbate skeletal fragility (29, 30).

Emerging evidence has highlighted the potential impact of glucose-lowering therapies on muscle mass, which may in turn influence bone health in patients with type 2 diabetes (31). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), while highly effective for glycemic control and weight reduction, have been associated with variable degrees of lean body mass loss, with some studies reporting that 40%: 60% of total weight loss may comprise lean mass (32). Although the clinical significance of this phenomenon remains debated, it is particularly relevant in older adults and those with pre-existing sarcopenia, who may be at greater risk of functional decline and fractures (33).

Importantly, sarcopenia and osteoporosis frequently co-exist as “osteosarcopenia,” a condition associated with higher fracture risk and worse clinical outcomes. In this context, nutritional status: as captured by GNRI: may serve as a critical link, because inadequate protein intake and energy deficiency not only contribute to bone loss but also exacerbate muscle wasting. Therefore, in patients receiving GLP-1 RAs or other weight-lowering therapies, regular assessment of nutritional risk using tools such as GNRI could help identify individuals who may benefit from targeted nutritional support and resistance exercise interventions to preserve both muscle and bone mass.

Further prospective studies are needed to explore whether nutritional optimization can mitigate therapy-induced lean mass loss and its skeletal consequences.

The conclusions of this study should be interpreted with consideration of the following limitations. First, as a single-center retrospective investigation, it is inherently susceptible to selection bias, and the design precludes the inference of a causal relationship between GNRI and PMOP; thus, the findings necessitate validation through prospective studies. Second, the cohort consisted solely of hospitalized patients, who likely present with greater disease severity and higher nutritional risk compared to the general community population. This may limit the generalizability of our results.

Third, despite adjusting for several known confounders, important variables potentially influencing bone metabolism such as precise postmenopausal duration, detailed dietary calcium intake, habitual physical activity levels, and the specific use of certain glucose-lowering medications were not fully accounted for, potentially leading to residual confounding. eGFR was collected and showed no significant difference between the two groups (p > 0.05); therefore, it was not entered into the multivariate logistic regression model. Nevertheless, given the well-established role of renal function in bone metabolism, we acknowledge that residual confounding related to renal function cannot be completely excluded, and future studies with larger sample sizes and more detailed renal function stratification are warranted.

Fourth, parathyroid hormone (PTH) levels were not measured in this study, as they were not part of the routine clinical protocol during the study period. Given the well-recognized role of secondary hyperparathyroidism in diabetic bone disease: particularly in the context of vitamin D deficiency and potential renal impairment: the absence of PTH data limits our ability to fully characterize the mechanisms underlying the observed associations. Fifth, acid: base balance parameters (e.g., serum bicarbonate) were not available in this study. Chronic metabolic acidosis, which may develop in T2DM patients with declining renal function or suboptimal glycemic control, is known to promote bone resorption through buffering mechanisms that mobilize calcium and phosphate from the bone matrix.

The absence of these data precludes assessment of this potential confounder and represents an additional limitation in interpreting the mechanistic pathways linking nutritional status to bone health. Sixth, the study did not incorporate a broader panel of bone turnover biomarkers or advanced imaging modalities to assess bone microstructure. Consequently, a deeper exploration of the underlying mechanisms from the perspectives of dynamic bone remodeling equilibrium and bone quality was not feasible.

5

Conclusion

In summary, among postmenopausal women with T2DM, a higher GNRI value is independently associated with a lower risk of osteoporosis. A lower GNRI level is significantly associated with an increased risk of osteoporosis and demonstrates moderate discriminatory ability for identifying this condition in the study population. These findings suggest that GNRI may serve as a simple and useful auxiliary indicator for assessing skeletal health risk in postmenopausal T2DM patients. For individuals with low GNRI values, enhanced nutritional evaluation and bone mineral density monitoring should be considered to facilitate early prevention and management of osteoporosis and related fractures.

Further prospective studies are warranted to validate the clinical utility of GNRI in this population.

Edited by: Gianluca Rizzo, Independent researcher, Messina, Italy

Reviewed by: Barbara Ciastek, University of Opole, Poland

Jian-min Liu, Shanghai Jiao Tong University, China

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMD, Bone mineral density; BMI, Body mass index; DXA, Dual-energy X-ray absorptiometry; GNRI, Geriatric Nutritional Risk Index; OP, Osteoporosis; PMOP, Postmenopausal osteoporosis; ROC, Receiver operating characteristic; T2DM, Type 2 diabetes mellitus; TC, Total cholesterol; TG, Triglycerides.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The study protocol was approved by the Ethical Committee of The Sixth Affiliated Hospital of Xinjiang Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required from the participants or the participants’ legal guardians/next of kin in accordance with the national legislation and institutional requirements.

Author contributions

AH: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing: original draft, Writing: review & editing. HL: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing: original draft, Writing: review & editing. WLiu: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Visualization, Writing: original draft, Writing: review & editing. WLi: Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Software, Supervision, Validation, Writing: original draft, Writing: review & editing.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that Generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Fang W Peng P Xiao F He W Wei Q He M . A negative association between total cholesterol and bone mineral density in US adult women . Front Nutr . (2022 ) 9 :937352 . doi: 10.3389/fnut.2022.937352 , 36245496 PMC9562045
2. Schwartz AV Sellmeyer DE . Diabetes, fracture, and bone fragility . Curr Osteoporos Rep . (2007 ) 5 :105Not reported11 . doi: 10.1007/s11914-007-0025-x , 17925191
3. Shanbhogue VV Hansen S Frost M Jørgensen NR Hermann AP Henriksen JE . Bone geometry, volumetric density, microarchitecture, and estimated bone strength assessed by HR-pQCT in adult patients with type 1 diabetes mellitus . J Bone Miner Res . (2015 ) 30 :2188Not reported99 . doi: 10.1002/jbmr.2573 , 26096924
4. Tao B Shen X Li G Wu X Yang Y Sheng C . New evidence, creative insights, and strategic solutions: advancing the understanding and practice of diabetes osteoporosis . J Diabetes . (2025 ) 17 :e70091 . doi: 10.1111/1753-0407.70091 , 40265523 PMC12015633
5. Lips P Eekhoff M van Schoor N Oosterwerff M de Jongh R Krul-Poel Y . Vitamin D and type 2 diabetes . J Steroid Biochem Mol Biol . (2017 ) 173 :280Not reported5 . doi: 10.1016/j.jsbmb.2016.11.021 , 27932304
6. Mor A Pawlak K Kalaska B Domaniewski T Sieklucka B Zieminska M . Modulation of the paracrine kynurenic system in bone as a new regulator of osteoblastogenesis and bone mineral status in an animal model of chronic kidney disease treated with LP533401 . Int J Mol Sci . (2020 ) 21 :5979 . doi: 10.3390/ijms21175979 , 32825192 PMC7503245
7. Kraut JA Madias NE . Adverse effects of the metabolic acidosis of chronic kidney disease . Adv Chronic Kidney Dis . (2017 ) 24 :289Not reported97 . doi: 10.1053/j.ackd.2017.06.005 , 29031355
8. Ji Y Geng N Niu Y Zhao H Fei W Chen S . Relationship between geriatric nutritional risk index and osteoporosis in type 2 diabetes in northern China . BMC Endocr Disord . (2022 ) 22 :308 . doi: 10.1186/s12902-022-01215-z , 36494810 PMC9733244
9. Euser AM Zoccali C Jager KJ Dekker FW . Cohort studies: prospective versus retrospective . Nephron . (2009 ) 113 :c214Not reported7 . doi: 10.1159/000235241 , 19690438
10. Chinese Society of Osteoporosis and Bone Mineral ResearchZhang Z . Guidelines for the diagnosis and management of primary osteoporosis (2022) . Chinese Journal of Osteoporosis and Bone Mineral Research . (2022 ) 15 :573Not reported611 .
11. Liu J Zhu D Mu Y Xia W . Management of fracture risk in patients with diabetes-Chinese expert consensus . J Diabetes . (2019 ) 11 :906Not reported19 . doi: 10.1111/1753-0407.12962 , 31219236
12. Chinese Geriatrics Society. Chinese clinical guidelines for the prevention and treatment of type 2 diabetes mellitus in the elderly (2022 edition) . Chinese Journal of Diabetes . (2022 ) 30 :2Not reported51 .
13. Bouillanne O Morineau G Dupont C Coulombel I Vincent J Nicolis I . Geriatric nutritional risk index: a new index for evaluating at-risk elderly medical patients . Am J Clin Nutr . (2005 ) 82 :777Not reported83 . doi: 10.1093/ajcn/82.4.777 , 16210706
14. Li Z Zhao W Lin X Li F . AI algorithms for accurate prediction of osteoporotic fractures in patients with diabetes: an up-to-date review . J Orthop Surg Res . (2023 ) 18 :956 . doi: 10.1186/s13018-023-04446-5 , 38087332 PMC10714483
15. Karim L Bouxsein ML . Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties . Bone . (2016 ) 82 :21Not reported7 . doi: 10.1016/j.bone.2015.07.028 , 26211993 PMC4679472
16. Bonjour J . Dietary protein: an essential nutrient for bone health . J Am Coll Nutr . (2005 ) 24 :526SNot reported36S . doi: 10.1080/07315724.2005.10719501 , 16373952
17. Rizzoli R Biver E Brennan-Speranza TC . Nutritional intake and bone health . Lancet Diabetes Endo . (2021 ) 9 :606Not reported21 . doi: 10.1016/S2213-8587(21)00119-4 , 34242583
18. Jiang Z Cai X Lan W Jin Z Liu J Tang F . Predictive role of the geriatric nutritional risk index in all-cause and cardiovascular mortality among elderly patients with osteoarthritis . BMC Geriatr . (2025 ) 25 :592 . doi: 10.1186/s12877-025-06225-9 , 40764522 PMC12326807
19. Fujita S Nagata K Kinjo K Mimata H Sonoda T Mine K . The effect of diabetes medication on the scores of the GNRI and CONUT nutritional indices: cross-sectional and longitudinal retrospective studies . Clin Transl Sci . (2025 ) 18 :e70423 . doi: 10.1111/cts.70423 , 41263161 PMC12631171
20. Rentflejsz J Wojszel ZB . Diabetes mellitus should be considered while Analysing sarcopenia-related biomarkers . J Clin Med . (2024 ) 13 :1107 . doi: 10.3390/jcm13041107 , 38398421 PMC10889814
21. Elsayed NA Aleppo G Aroda VR Bannuru RR Brown FM Bruemmer D . 2. Classification and diagnosis of diabetes: standards of care in Diabetes-2023 . Diabetes Care . (2023 ) 46 :S19Not reported40 . doi: 10.2337/dc23-S002 36507649 PMC9810477
22. Kirk B Miller S Zanker J Duque G . A clinical guide to the pathophysiology, diagnosis and treatment of osteosarcopenia . Maturitas . (2020 ) 140 :27Not reported33 . doi: 10.1016/j.maturitas.2020.05.012 , 32972632
23. Jukic AMZ Steiner AZ Baird DD . Association between serum 25-hydroxyvitamin D and ovarian reserve in premenopausal women . Menopause . (2015 ) 22 :312Not reported6 . doi: 10.1097/GME.0000000000000312 , 25093721 PMC4317384
24. Demir Cendek B Bayraktar B Sapmaz MA Yıldırım AE Can Ibanoglu M Engin Ustun Y . The role of inflammatory and nutritional indices in postmenopausal osteoporosis: a retrospective study . J Clin Med . (2024 ) 13 :7741 . doi: 10.3390/jcm13247741 , 39768664 PMC11678489
25. Geng J Qiu Y Li Y Li J Liao R Du H . Associations between 25-hydroxyvitamin D, kidney function, and insulin resistance among adults in the United States of America . Front Nutr . (2021 ) 8 :716878 . doi: 10.3389/fnut.2021.716878 , 35242790 PMC8885514
26. Jung Y Ay B Cyr SM Tognoni CM Klovdahl K Matthias J . Amyloid-β neuropathology induces bone loss in male mice by suppressing bone formation and enhancing bone resorption . Bone Rep . (2024 ) 21 :101771 . doi: 10.1016/j.bonr.2024.101771 , 38725879 PMC11078651
27. Al-Bashaireh AM Haddad LG Weaver M Chengguo X Kelly DL Yoon S . The effect of tobacco smoking on bone mass: an overview of pathophysiologic mechanisms . J Osteoporos . (2018 ) 2018 :1206235 . doi: 10.1155/2018/1206235 , 30631414 PMC6304634
28. Zeng F Xu JH Yao RY Mo W Wu XQ . Research progress on sequential drug therapy for primary osteoporosis . Clin Medication J . (2025 ) 23 :1Not reported5 .
29. Cereda E Zagami A Vanotti A Piffer S Pedrolli C . Geriatric nutritional risk index and overall-cause mortality prediction in institutionalised elderly: a 3-year survival analysis . Clin Nutr . (2008 ) 27 :717Not reported23 . doi: 10.1016/j.clnu.2008.07.005 , 18774626
30. Shi P Gong H Lyu L Liu S Jia S Li C . Low bone turnover is associated with advanced glycation end-products, oxidative stress, and inflammation induced by type 2 diabetes mellitus . FASEB J . (2024 ) 38 :e23871 . doi: 10.1096/fj.202400790R , 39109498
31. Bloomgarden ZT . Monitoring sarcopenia with incretin receptor activator treatment . J Diabetes . (2025 ) 17 :e70117 . doi: 10.1111/1753-0407.70117 , 40530788 PMC12175196
32. Wen J Ansari U Shehabat M Ansari Z Syed B Razick A . The potential of SARMs and Antimyostatin agents in addressing lean body mass loss from GLP-1 agonists: a literature review . J Diabetes . (2025 ) 17 :e70119 . doi: 10.1111/1753-0407.70119 , 40739991 PMC12311314
33. Bloomgarden Z . Recent articles-skeletal muscle and other topics in diabetes . J Diabetes . (2025 ) 17 :e70169 . doi: 10.1111/1753-0407.70169 , 41253694 PMC12626741
Publication and source details

Original title: Association between the nutritional risk index and postmenopausal osteoporosis in patients with type 2 diabetes mellitus

Abuduwupuer Haibier; Hang Lin; Wei Liu; Wencui Li

Frontiers in Nutrition · 2026

* Correspondence: Wei Liu, 262819@163.com; Wencui Li, 13923750767@163.comCopyright © 2026 Haibier, Lin, Liu and Li.2026Haibier, Lin, Liu and Lihttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Sanming Project of Medicine in Shenzhen (No. SZSM202311008).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T23:23:45.877055+00:00

DOI: 10.3389/fnut.2026.1801604 · PMC13094402